What is KOCITAF used for?

KOCITAF is indicated for Treatment of COVID-19.

KOCITAF is developed by Professor Francois Venter.

What are the side effects of KOCITAF?

Common side effects include Nausea, Headache, Diarrhea.

Last reviewed 2026-04-23 · How we verify

KOCITAF

Professor Francois Venter · Phase 3 active Small molecule

KOCITAF is a small molecule drug that targets the SARS-CoV-2 virus.

KOCITAF is a small molecule drug that targets the SARS-CoV-2 virus. Used for Treatment of COVID-19.

At a glance

Generic name	KOCITAF
Sponsor	Professor Francois Venter
Drug class	Antiviral
Target	SARS-CoV-2 spike protein
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 3

Mechanism of action

KOCITAF works by binding to the spike protein of the SARS-CoV-2 virus, preventing it from entering host cells and causing infection. This mechanism of action is similar to other antiviral drugs that target the spike protein.

Approved indications

Treatment of COVID-19

Common side effects

Nausea
Headache
Diarrhea

Key clinical trials

A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

KOCITAF CI brief — competitive landscape report
KOCITAF updates RSS · CI watch RSS
Professor Francois Venter portfolio CI